Immunosuppression in liver transplantation

被引：18

作者：

Cattral, MS

Lilly, LB

Levy, GA

机构：

[1] Univ Toronto, Toronto Gen Hosp, Univ Hlth Network, Dept Surg, Toronto, ON M5G 2C4, Canada

[2] Univ Toronto, Toronto Gen Hosp, Univ Hlth Network, Dept Med, Toronto, ON M5G 2C4, Canada

[3] Univ Toronto, Toronto Gen Hosp, Univ Hlth Network, Multi Organ Transplant Program, Toronto, ON M5G 2C4, Canada

来源：

SEMINARS IN LIVER DISEASE | 2000年 / 20卷 / 04期

关键词：

liver transplantation; immunosuppression; rejection;

D O I：

10.1055/s-2000-13160

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Prevention of graft rejection while minimizing morbidity remains the single most important objective in liver transplantation. Advances in immunosuppression have provided excellent patient and graft survival with relatively low incidences of acute rejection. However it is apparent that the toxicity of the present immunosuppressive drugs accounts for much of the morbidity after transplantation. Attention is now being focused on combination drug therapies to reduce morbidity while maintaining the excellent results achieved with present immunosuppressive agents.

引用

页码：523 / 531

页数：9

共 81 条

[51]

MCDIARMID SV, 1995, TRANSPLANTATION, V59, P530

[52] CYCLOSPORINE - 5 YEARS EXPERIENCE IN CADAVERIC RENAL-TRANSPLANTATION [J].